Valeant Pharma (VRX) to Acquire Sprout Pharmaceuticals in ~$1B + Milestones Deal
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
BMO Capital Remains Bullish on Valeant Pharma (VRX) Following Announced Acquisition of 'Female Viagra' Maker Sprout Pharma
August 20, 2015 11:29 AM EDTBMO Capital reiterated an Outperform rating and $285 price target on Valeant Pharmaceuticals (NYSE: VRX) following the announced acquisition on Sprout Pharmaceuticals. Sprout recently received FDA approval for Addyi (filbanserin) , a non-hormonal pill for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD), on August 18th. Valeant will pay ~$1 billion... More
Palatin Technologies (PTN) on Watch as Rival Sprout Said Near Deal to Be Acquired
August 20, 2015 6:21 AM EDTPalatin Technologies (NYSE: PTN) is on watch amid reports from the Wall Street Journal that Valeant Pharmaceuticals (NYSE: VRX) is near a deal to by rival Sprout Pharmaceuticals, which just won FDA approval for a drug to boost a woman's libido, for $1 billion.
... MoreValeant to buy 'female Viagra' maker Sprout Pharma
August 20, 2015 12:25 AM EDTBy Natalie Grover, Caroline Humer and Ransdell Pierson
(Reuters) - Canada's Valeant Pharmaceuticals International Inc (NYSE: VRX) (NYSE: VRX) said on Thursday it would buy Sprout Pharmaceuticals, which makes a controversial new drug to treat low sexual desire in women, for about $1 billion.
Valeant shares fell about 5 percent as Wall Street questioned whether the acquisition would be too risky for the big drugmaker, which has done six other deals this year.
The U.S. Food and Drug Administration approved Sprout's Addyi on Tuesday after... More